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ABSTRACT
Background: Currently, no generally approved
medical treatment can delay the onset of age-
related macular degeneration (AMD) or slow the
progression of degenerative changes. Repur-
posing drugs with beneficial effects on AMD
pathophysiology offers a route to new treat-
ments which is faster, cost-effective, and safer
for patients. Recent studies indicate a potential
role for metformin in delaying AMD develop-
ment and progression. In this context, we con-
ducted a systematic review and meta-analysis to
look for beneficial associations between met-
formin and AMD.
Methods: We systematically searched Medline
and Embase (via Ovid), Web of Science, and
ClinicalTrials.gov databases for clinical studies
in humans that examined the associations
between metformin treatment and AMD pub-
lished from inception to February 2021. We
calculated pooled odds ratio (OR) with 95%
confidence interval (CI) considering a random
effect model in the meta-analysis.
Results: Five retrospective studies met the
inclusion criteria. There are no prospective
studies that have reported the effect of met-
formin in AMD. The meta-analysis showed that
people taking metformin were less likely to have
AMD although statistical significance was not
met (pooled adjusted OR = 0.80, 95% CI
0.54–1.05, I2 = 98.8%). Subgroup analysis of the
association between metformin and early and
late AMD could not be performed since the data
was not available from the included studies.
Conclusions: Analysis of retrospective data
suggests a signal that metformin may be asso-
ciated with decreased risk of any AMD. It should
be interpreted with caution because of the fail-
ure to meet statistical significance, the small
number of studies, and the limitation of routine
record data. However prospective studies are
warranted in generalizable populations without
diabetes, of varied ethnicities, and AMD stages.
Clinical trials are needed to determine if met-
formin has efficacy in treating early and late-
stage AMD.
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Metformin is postulated to delay ageing
and ageing-related diseases, including age-
related macular degeneration.
We performed a systematic review and
meta-analysis on five retrospective
populations studies investigating
metformin use and presence of AMD,
showing an odds ratio of 0.80 (95% CI
0.54–1.05)
Laboratory and clinical studies support a
potential role for metformin in delaying
AMD development and progression
through multiple modes of action.
There are no published data from
prospective studies of the effect of
metformin on AMD. Prospective studies
are needed to further investigate this
positive signal.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14308706
INTRODUCTION
Age-related macular degeneration (AMD) is the
most common cause of blindness in high-in-
come countries with prevalence rising expo-
nentially with age [1]. Globally, AMD is a top
five cause of vision loss [2]. In the next decades
with aging population, the number of people
with AMD in the world is estimated to increase
by 50% to 288 million in 2040 with the highest
burden in Asia [1]. AMD can be divided into
early and advanced stages [3] with the latter
having serious impacts on vision. Advanced
AMD has two forms: (1) atrophic/dry/non-neo-
vascular and (2) neovascular/wet/exudative [4].
Treatments for AMD are limited to arresting
neovascular AMD (nAMD). Anti-vascular
endothelial growth factor (anti-VEGF) thera-
pies, delivered by intravitreal injections, are
successful at treating the active neovascular
component of nAMD [5]. However, treatment is
not curative, the benefit does not extend to
atrophic or fibrotic changes, and requires a ser-
ies of expensive injections over a long period of
time [6]. Unfortunately, there is currently no
therapy for geographic atrophy (GA) or other
forms of degenerative AMD which in all
account for approximately 90% of the disease
burden [7]. Despite widespread opinion on
antioxidant supplementation, the evidence of
their benefit is weak [8–10]. The Age-Related Eye
Disease Study (AREDS) [11] did not meet pri-
mary endpoints, and evidence of effect was
based on post hoc subgroup analysis [12, 13].
Age-Related Eye Disease Study 2 (AREDS2) did
not provide data on whether antioxidants are
effective in preventing AMD progression as it
did not include a placebo arm [14, 15].
Currently, dry or non-neovascular AMD
remains an unmet medical need, and the com-
monest cause of registered blindness in high-
income countries [16]. GA is the target of clin-
ical trials for new treatments, but patients with
non-GA, enlarging drusen, drusenoid pigment
epithelial detachment (PED), and vitelliform-
type degeneration are currently underserved in
drug development pipelines. New therapies that
are effective in the prevention of AMD and
limiting its progression are urgently needed,
since its incidence is increasing and because of
limitations on existing therapies. Developing
new drugs is expensive in cost and time [17].
Repurposing existing drugs to find new func-
tional benefits or indications can be an alter-
native. There is growing interest in metformin
as a candidate drug for treating AMD and
reducing its progression. This is because of its
antioxidant, anti-inflammatory, antiangio-
genic, and antifibrotic effects [18–21]. Met-
formin is postulated to delay ageing and ageing-
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related diseases [22, 23]. Metformin is well tol-
erated and has a good safety profile with a long
history as a treatment for type 2 diabetes mel-
litus (T2DM) [24]. Therefore, we performed a
systematic review and conducted a meta-anal-
ysis underpinning the potential use of met-
formin in AMD.
METHOD
Eligibility Criteria and Literature Search
Strategy
We performed a systematic review and meta-
analysis following the guidelines of the Pre-
ferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [25] and
the Strengthening the Reporting of Observa-
tional studies in Epidemiology (STROBE) state-
ment [26]. This article is based on previously
conducted studies and does not contain any
new studies with human participants or animals
performed by any of the authors. Studies were
included if they met the following criteria: (1)
studies in human; (2) one study objective is to
explore the association between metformin
treatment and the risk of AMD; (3) there is
control group; (4) the studies provided the
effect estimate or calculable information from
the available data presented in the article; (5)
peer reviewed article; (6) the studies stated the
definition and classification of AMD clearly in
the paper; (7) published in English. The latest
information published was to be used if there
were serial publications using the same subjects.
A systematic electronic search of Medline
and Embase (via Ovid) and Web of Science
Databases including conference papers and
abstracts from the earliest record in databases
until February 2021 was performed. An addi-
tional search was performed on ClinicalTrials.-
gov to capture unpublished studies. The search
strategy included the generic keyword combi-
nations of ‘‘metformin’’ and ‘‘macular degener-
ation’’ with further details listed in
Supplementary Material A. The references of
eligible studies were also searched, and expert
reference suggestion was included to make sure
all relevant materials were captured.
Study Selection
We used Covidence software (Veritas Health
Innovation, https://www.covidence.org) for
data extraction, data organisation, and litera-
ture screening. After the duplicate check, two
reviewers independently identified relevant
titles and abstracts. Full-text articles were
reviewed if on the basis of the title and abstract
they appeared to meet the inclusion criteria, or
if there was any uncertainty.
Data Collection and Study Quality
Assessment
Data obtained included data source, sample
size, study design, study period, AMD diagnos-
tic criteria, the unadjusted and adjusted effect
estimate and/or calculable information from
the available data, adjustments for potential
confounders, and study outcome. Quality of
study assessment was conducted using the
Downs and Black checklist [27, 28], which
includes 27 items to assess the quality of
reporting (10 items), external validity (3 items),
internal validity including bias and confound-
ing (13 items), and statistical power (1 item).
The original Downs and Black checklist
allows a cumulative score of 32 points, one item
having a maximum two points in the quality of
reporting section and five points in the statis-
tical power section. An adjustment was made to
the scoring of item 27 that refers to the statis-
tical power of the study. We rated a single point
if the study had sufficient power to detect a
clinically important effect, instead of scoring
based on the available range of study powers.
Therefore, the maximum score for the checklist
was 28. The Downs and Black score ranges were
assigned according to quality levels into four
groups: less than 14 (low), 14–18 (moderate),
19–23 (good), and more than 23 (excellent)
[29]. The quality of each study was indepen-
dently assessed by two reviewers, with discrep-
ancies resolved through discussion.
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Data Synthesis and Statistical Analysis
We converted any kind of risk estimates and
any calculable information reported from the
included studies to an odds ratio (OR) for
pooled result calculation. Heterogeneity
between studies was tested by Cochrane chi-
square v2 (Cochran Q) and I2 statistic. The
P value less than 0.1 was set as a threshold for
statistical significance in using Cochran’s Q sta-
tistical test to assess heterogeneity [30].
Threshold interpretation of heterogeneity in I2
statistic was considered as low, moderate, and
high for I2 upper limits of 25%, 50%, and 75%,
respectively [31]. A sensitivity analysis was
conducted by removing single studies to deter-
mine if any individual study has a significant
impact on the pooled OR. All analyses were
conducted using STATA software version 16.1
(StataCorp LLC, Texas, USA).
RESULTS
Literature Systematic Search
A total of 204 records were screened from the
literature search. Figure 1 shows the study
selection process for articles included in meta-
analysis. There was no disagreement between
the two independent reviewers who conducted
the study selection. We found five published
retrospective studies using AMD diagnosis cri-
teria based on the International Classification of
Diseases Ninth and/or Tenth Edition (ICD-9,
ICD-10) listed in Supplementary Material B with
metformin medication documented from the
medical records examining the relationship
between AMD and the use of metformin medi-
cations (Table 1). Table 2 provides the method-
ological quality assessment of each included
study according to the Downs and Black tool.
All included studies were of moderate quality
with scores ranging from 15 to 17 points, out of
a possible 28 points.
Three studies were conducted in the USA.
The first study [32] analysed 7788 patient
records (1947 AMD and 5841 non-AMD) of
people aged 55 years and older from the
University of Florida electronic health record
who attended at least four times from June 2011
to June 2017, and found that metformin was
associated with substantially decreased risk of
developing any AMD (ICD-9 diagnostic codes)
using univariate analysis (OR 0.39; 95% CI
0.31–0.49, P\0.001) and conditional multi-
variable logistic regression (OR 0.58; 95% CI
0.43–0.79, P\0.001). In a subgroup analysis
just of patients with diabetes, metformin use
had decreased odds of developing any AMD (OR
0.70; 95% CI 0.49–0.98, P = 0.043). This study
suggests a large reduction in risk of any AMD
associated with metformin use, but is limited by
its retrospective use of routine health records.
Causality of course is not demonstrated since
other inevitable exposure cannot be controlled
in a non-randomised study and possibility of
data misclassification.
The second study in the USA [33] gathered
data from University of California San Francisco
electronic medical record of people aged
60 years and older with diabetes, and having an
ophthalmology encounter from April 2012 to
August 2019. It reported that in 3120 patients,
metformin was associated with decreased odds
of any AMD (OR 0.70; 95% CI 0.55–0.88,
P = 0.003) and non-neovascular AMD (OR 0.59;
95% CI 0.46–0.77, P\ 0.001) using propensity
score-weighted logistic regression models. It
should be noted that this study only included
patients who had seen an ophthalmologist, and
this is more likely if they have AMD. This is a
potential source of bias.
The third study in the USA [34] used data of
624,780 patient records (312,404 AMD and
312,376 non-AMD) of people aged 55 years and
older who had eye examinations at least two
times during the previous 12 months from IBM
MarketScan Commercial and Medicare Supple-
mental Databases from January 2008 to
December 2017. In multivariable logistic
regression analysis, the use of metformin was
reported to slightly lower the odds of having
any AMD in a whole study population (OR 0.94;
95% CI 0.92–0.96, P\0.001) and in a subgroup
of people with diabetes (OR 0.95; 95% CI
0.93–0.97, P\ 0.001). The metformin doses of
1–270 g over 2 years had the highest reduction
in odds of having AMD (OR 0.91; 95% CI
0.89–0.94, P\ 0.001) compared to higher doses
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in a whole study population. This study mat-
ched the risk factors and comorbidities within
1 year before the index date, while metformin
exposure was within 2 years before the index
date. This introduced a risk of bias in sample
selection since the comorbidities may have
developed after metformin exposure.
A study in Taiwan [35] was a population-
based retrospective cohort study in patients
with T2DM (45,524 patients taking metformin
and 22,681 control subjects) using the Taiwan
National Health Insurance Research Database
from 2001 to 2013. Cox regression analysis
demonstrated substantially less AMD develop-
ing within the metformin group after adjusting
for age, sex, and systemic comorbidities com-
pared to controls (HR 0.54; 95% CI 0.50–0.58,
P\ 0.001). People in the metformin group were
still at a lower risk of AMD after adjustment of
propensity score in the Cox regression analysis
(HR 0.57; 95% CI 0.52–0.63, P\0.001).
Decreasing risk of AMD was observed with a
longer duration and higher dose of metformin
(Cox regression analysis, P\ 0.05).
A study in Korea using National Health
Insurance Service data [36] included 2330 cases
of AMD and 23,278 controls from patient
records of people who were diagnosed with
diabetes or cardiovascular diseases in 2002.
Metformin users had no reduction in any AMD
(ICD-10 diagnostic code) risk (adjusted OR 1.15,
95% CI 0.91–1.45). The study concluded that
metformin was not associated with a decreased
risk of any AMD after adjusting for
Fig. 1 PRISMA flowchart of study selection process
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socioeconomic status, healthcare resource uti-
lization, combined medication use, and
comorbidities. Compared to other studies, only
this study included people with cardiovascular
diseases as the study population. This is a
potential source of bias as cardiovascular disease
is reported to have an association with AMD
[37–40].
We identified that there are no published
prospective studies that have investigated met-
formin in AMD. Only two studies in the meta-
analysis presented the association of metformin
and AMD in people with and without diabetes
[32, 34] and one study in people with diabetes
or cardiovascular disease [36]. A phase 2 ran-
domized clinical trial study began in 2016 to
investigate the effects of metformin on the
progression of geographic atrophy and drusen
in AMD in patients without diabetes initiated
by University of California; no data or results
have been reported (ClinicalTrials.gov Identifier
NCT02684578). The clinical trials completion
date is expected in October 2021.
META-ANALYSIS
We performed a meta-analysis for the associa-
tion of metformin and any AMD in people with
diabetes. We could not generalize the results in
people without diabetes, as only two studies
reported data in this group [32, 34]. We anal-
ysed ‘any AMD’ since all studies included all
AMD, not only atrophic and neovascular AMD,
but also unspecified form of macular degenera-
tion (Supplementary Material B). Only one
study presented data of an AMD subtype, non-
neovascular AMD, in the analysis [33]. Thus, it
is not possible to perform meta-analysis by
classifying the AMD subtypes.
The forest plot of our meta-analysis from the
adjusted effect estimates of five retrospective
studies is shown in Fig. 2. The overall OR of any
AMD from metformin use was 0.80 with 95% CI
0.54–1.05. In a sensitivity analysis, the OR
remained stable and the upper limit of the
confidence interval remained close to 1.0,
affecting the statistical significance (removing
study by Blitzer et al. [34]: OR 0.75, 95% CI
0.52–0.97, P\ 0.001, I2 = 87.1%; Stewart et al.
[33]: OR 0.82, 95% CI 0.53–1.12, P\ 0.001,
I2 = 99.1%; Brown et al. [32]: OR 0.82, 95% CI
0.54–1.11, P\ 0.001, I2 = 99.1%; Chen et al.
[35]: OR 0.87, 95% CI 0.70–1.05, P = 0.002,
I2 = 79.7%; Lee et al. [36]: 0.72, 95% CI
0.44–1.01, P\ 0.001, I2 = 99.1%).
The heterogeneity of included studies was
high (I2 = 98.8%). After excluding study by
Chen et al. [35] and Blitzer et al. [34], we
observed that the heterogeneity I2 decreased
from 98.8% to 79.7% and 87.1%. We did not
perform stratified analysis across a number of
participants characteristic because of the small
number of studies included.
DISCUSSION
In this novel systematic review and meta-anal-
ysis, we found a beneficial odds ratio between
metformin use and decreased risk of AMD from
retrospective data, although it is not statistically
significant. Retrospective, routinely collected
data will not determine whether metformin will
Table 2 Results of study quality assessment using the Downs and Black assessment tool
Study ID Reporting External validity Internal validity Power Total
Bias Confounding
Blitzer et al. [34] 9 1 3 3 1 17
Stewart et al. [33] 8 1 2 3 1 15
Brown et al. [32] 9 1 3 3 1 17
Chen et al. [35] 9 1 3 3 1 17
Lee et al. [36] 9 1 3 3 1 17
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be of benefit for AMD, but the signal found
justifies further research and clinical investiga-
tion. AMD is by far the commonest cause of
blindness in wealthy countries with currently
no treatment for the majority.
In the epidemiological studies, people with
diabetes have shown a greater burden of AMD
[41–43]. The pathophysiology of AMD is
thought to share some pathways with diabetes,
especially oxidative stress and chronic inflam-
mation [41, 42, 44–48]. Laboratory and clinical
studies have investigated the potential role of
metformin in suppression of oxidative stress
[49] and inflammation [50], supporting the
hypothesis of its potential role in delaying AMD
progression.
Metformin is considered to have a beneficial
role in ageing-related diseases owing to its
antioxidant [51–55] and anti-inflammatory
effects [50]. Metformin suppresses oxidative
stress on retinal pigment epithelium (RPE) by
stimulating the AMPK (adenosine monophos-
phate-activated protein kinase) signalling
pathway in an AMD mouse model [20]. The
model uses sodium iodate to cause oxidative
damage to RPE that imitates the oxidative stress
in early AMD. AMPK is a cellular mechanism
that is activated in response to metabolic stress
conditions to restore energy homeostasis
through balancing the adenosine triphosphate
(ATP) levels [56]. ATP is vital to meet the high
metabolic demands of the retina and RPE
[57, 58]. Increased ATP levels are observed in the
retinal degenerative mouse model treated with
metformin [20].
Ageing and oxidative stress are not only
known for causing increased intracellular dam-
age but are also thought to be related to
impaired autophagy [59]. Metformin is able to
induce autophagy and reduce apoptosis of reti-
nal cells caused by vital dyes, indocyanine green
(ICG) and brilliant blue G (BBG), in studies on
human RPE cell lines (ARPE-19) and rat models
[60]. This suggests the possible role of met-
formin in improving autophagy processes in
AMD. Autophagy is important in cellular
homeostasis for clearance of dysfunctional cell
components [61]. A significant decrease in cel-
lular autophagy is presumed to play an impor-
tant role in development of AMD [62–64].
A systematic review and meta-analysis of
metformin in neurodegenerative disease inclu-
ded 14 studies (seven cohorts, four cross-sec-
tional, two RCTs, and one case–control) showed
a protective effect against neurodegenerative
diseases in patients with T2DM including
dementia, Alzheimer’s disease, and cognitive
impairment in the elderly [22]. These findings
in other diseases that associated with age and
AMD [39–41, 65] promote a potential role for
metformin delaying AMD and preventing its
progression.
Abnormal angiogenesis driven by VEGF
defines the neovascular form of AMD [66].
Metformin decreases levels of serum VEGF [67],
so might have an effect on the macula angio-
genic pathway. In mouse model and cultured
human umbilical vein endothelial cell (HUVEC)
studies of ischaemia-related retinopathy, met-
formin suppressed the vascular endothelial
growth factor receptor (VEGFr) Flk-1, the key
mediator of the angiogenic effects of VEGF [68].
Metformin is reported to reduce tumour pro-
gression with its antiangiogenic effect through
suppression of hypoxic factors [69]. However in
other studies, metformin has a cardioprotective
effect by inducing angiogenesis, reducing
angiogenic inhibitors, and increasing VEGFA
[70]. The contradictory results of different
studies on the angiogenic effects of metformin
are thought to be due to tissue-specific angio-
genic pathways [19, 71]. Further research is
needed to know the effect of metformin on
angiogenesis in nAMD.
The transdifferentiation of cells to myofi-
broblasts or epithelial–mesenchymal transition
(EMT) is related to subretinal fibrosis in AMD
[72]. Suppression of EMT in RPE is reported to
attenuate fibrosis [73], and metformin inhibits
hypoxia-induced EMT in keloid fibroblasts [74].
Thus, EMT is a potential target of metformin in
reducing fibrosis associated with late-stage
AMD, warranting further research.
We have followed PRISMA and STROBE
guidelines and using the adjusted effect esti-
mates in the meta-analysis to ensure reliable
results. However, some limitations need to be
considered when interpreting our results. First,
the literature search was limited to studies
written in English, so there might be a language
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bias. Second, significant heterogeneity between
studies exists, thereby limiting the strength of
conclusions from this meta-analysis. Third, the
population of included studies was based on US
and East Asian populations, thus further studies
in other locations and ethnicities are required.
Our meta-analysis only included patients with
diabetes as almost all patients routinely on
metformin have diabetes; however prospective
studies in non-diabetic populations are required
to determine if an association exists in patients
without diabetes. There is a first clinical trial
investigating the effects of metformin on the
progression of geographic atrophy and drusen
in AMD in patients without diabetes (Clini-
calTrials.gov Identifier NCT02684578). If this
trial is positive, larger multicentre phase 2 and 3
studies will be needed to determine the clinical
role of metformin in treating AMD.
Lastly, the studies included in our meta-
analysis are retrospective, relatively few in
number, and rely on data collected for other
purposes. Therefore, the results must be inter-
preted cautiously. They use broad diagnostic
categories of AMD so give no indication as to
whether metformin may be beneficial in pre-
venting progression of early AMD or improving
outcomes in more advanced AMD. However,
overall, they provide a signal of a possible ben-
eficial effect of metformin in AMD. Although it
is not statistically significant, further investiga-
tion into metformin’s effect on AMD in
prospective studies is warranted.
CONCLUSION
At present, data from five retrospective clinical
studies include four with large reductions in risk
of AMD associated with metformin. This is
reflected in our meta-analysis albeit with an OR
which does not meet significance at the 5%
level. Given metformin’s potential favourable
effects on AMD’s pathophysiology, a reduction
in risk seems plausible.
Prospective studies of metformin in AMD are
needed to elucidate fully the role of metformin
in AMD, as none reporting results were identi-
fied. The use of data and images from popula-
tions that are routinely screened for diabetic
retinopathy also provides an opportunity to
investigate metformin’s effect on AMD cost-ef-
ficiently before conducting randomized clinical
trials, since the data is collected prospectively
and systematically. There is certainly an unmet
treatment need at all stages of AMD which
metformin has an exciting potential to fulfil.
The mechanism of metformin as a treatment in
AMD might due to its antioxidant, anti-in-
flammatory, antiangiogenic, and antifibrotic
effects. Further study is needed to investigate
whether these beneficial effects on RPE cells and
in animal models are replicated in patients with
AMD.
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